Millennium Management
KYMR icon

Millennium Management’s Kymera Therapeutics KYMR Stock Holding History

Millennium Management’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-50,300
Closed -$1.25M – 6618
2022
Q4 		$1.25M Buy
50,300
+9,700
+24% +$259K ﹤0.01% 3940
2022
Q3 		$884K Buy
+40,600
New +$1.07M ﹤0.01% 4442
2022
Q2 		– Sell
-70,000
Closed -$2.96M – 7247
2022
Q1 		$2.96M Buy
+70,000
New +$2.96M ﹤0.01% 3508

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Millennium Management's KYMR Position: Q1 2026 in Review

Millennium Management sold out of Kymera Therapeutics (KYMR) in Q1 2026, closing a stake of 11,243 shares — an estimated $875K sold.

Millennium Management first reported a position in KYMR in Q3 2020 and held it in 14 quarters. The position peaked at $14M in Q1 2025. 256 funds tracked by Wall St. Rank hold KYMR as of Q1 2026.

  • Millennium Management reported no remaining Kymera Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Millennium Management sold 11,243 Kymera Therapeutics shares in Q1 2026, an estimated $875K.
  • Millennium Management first reported a position in Kymera Therapeutics in Q3 2020 and held it in 14 quarters.
  • Millennium Management's Kymera Therapeutics position peaked at $14M in Q1 2025.
  • 256 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.